AN EFFECTIVE GONOCOCCAL LIPOOLIGOSACCHARIDE (LOS) VACCINE: WE KNOW ENOUGH TO MAKE ONE

Mac Griffiths*, Copaud Bo, Inc., Wooster, USA

Background Long-lived gonococcal LOS IgG, induced during an initial challenge, prevented re-infection in 7/8 subjects (v = 1/6; p = 0.026), but treatment within three days of urethritis onset prevented an antibody response. This suggested that recidivism was related to early treatment. These data form the basis for an effective LOS vaccine.

Methods MS, NMR Spectroscopy and immunochemistry were used to structure the LOS made by the challenge strain, MS11mkC. Gonococci in scrapings of diagnostic slides were used to form LOS IgG. A multiplexed indirect immunofluorescent assay for LOS IgG was used to quantify LOS IgG.

Results MS11mkC LOS are genetically identical to those of MS11mkC. Gonococci in scrapings of diagnostic slides were LOS genotyped. A multiplexed indirect immunofluorescent assay for LOS IgG was used to quantify LOS IgG.

Conclusion Men with symptomatic urethritis had the highest GC culture yield (91%), followed by persons with recent GC NAAT+ (26–50%). Cultures in GC contacts had a modest yield (11%–23%). These criteria were appropriate for obtaining GC isolates for antimicrobial surveillance.

Disclosure No significant relationships.

OOROPHARYNGEAL GONORRHOEA IN THE ABSENCE OF UROGENITAL GONORRHOEA IN A SEXUAL NETWORK OF MALES AND FEMALES

Vincent Cormelle*, Catinia Bradshaw, Eric Chow, Deborah Williamson, Christopher Fairley, Melbourne Sexual Health Centre, Carlton, Australia; Alfred Health, Melbourne Sexual Health Centre, Carlton, Australia; The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Microbiological Diagnostic Unit Public Health Laboratory, Parkville, Australia; Melbourne Sexual Health Centre, Melbourne, Australia

Background We describe a sexual network consisting of two males and five females who were tested for gonorrhoea at